Gaining Weight While on Wegovy — Causes, Patterns and Next Steps

You're taking Wegovy every week and still gaining: what's actually going on

Imagine you have been on Wegovy for three or four months. The early weeks went well, appetite dropped, portions shrank, you felt the medicine working. Then, almost quietly, the numbers on the scale started climbing again. The instinct is to wonder whether something is wrong with the medicine, or with you. Usually it is neither.

The most common culprit at this stage is dose. Semaglutide is titrated gradually (starting at 0.25 mg and stepping up over several months) because the dose a person is on during titration is a stepping stone, not the level at which most people reach their full response. If appetite has returned before you have reached the 1.7 mg or 2.4 mg maintenance dose, the medicine is doing something, but not yet everything it is licensed to do. This is a conversation for your prescriber, not a reason to stop.

A second pattern is what some clinicians describe as adaptation. Over time the body adjusts its energy expenditure in response to weight loss, a well-documented physiological response. The appetite-suppressing effect of a stable dose can also feel less pronounced after several months at the same level, not because semaglutide has stopped binding to GLP-1 receptors, but because the gap between where you started and where you are now means the biological signal is competing with a recalibrated set point. A closer look at the specific reasons weight can return during treatment covers this in more depth.

Lifestyle drift is worth naming honestly too. Wegovy reduces appetite; it does not override the effect of consistently higher calorie intake if other things in life shift, stress, disrupted sleep, a change in routine. The full Wegovy overview explains how the medicine fits alongside, not instead of, reduced-calorie eating and activity.

The plateau problem: when the scale stops rather than climbs

There is a misconception worth letting go of gently: that a plateau means treatment is failing. In clinical trials, weight loss tends to slow and then level off well before the end of the study period, this is expected, not alarming. SURMOUNT and STEP trial data consistently show that the rate of loss peaks in the first few months and then flattens, even while total body weight remains substantially lower than at baseline.

A plateau is not the same as regain. If your weight has been stable for six to eight weeks at a lower level than you started, the medicine is likely still doing its job, holding you at a new equilibrium. The clinical question is whether that equilibrium is satisfactory and whether there is more to be achieved, which depends on factors including your current dose and any weight-related conditions being managed alongside treatment.

Genuine upward movement during active treatment (gaining more than a kilogram or two over several weeks) is different and worth flagging. The guide on weight gain specifically during Wegovy separates normal fluctuation from a pattern that warrants review. The NHS semaglutide patient information also notes that treatment response should be assessed at six months; if less than five percent of starting weight has been lost by that point, the prescriber will consider next steps. You can read the NHS's own guidance on semaglutide for further detail on the NHS semaglutide medicines page.

What happens to weight if Wegovy is stopped or delayed

The clearest evidence on weight gain and Wegovy comes not from people taking it but from people who stopped. Data from the STEP 1 extension study found that participants who discontinued semaglutide regained around two-thirds of the weight they had lost within a year of stopping, a finding that was widely reported and informed how clinical guidance frames Wegovy as an ongoing treatment rather than a short course.

This happens because the underlying biology does not change when treatment ends. Appetite returns, energy expenditure stays suppressed from the prior weight loss, and the conditions that made weight management difficult in the first place reassert themselves. It is not a character failing; it is physiology. What to expect after stopping Wegovy covers the evidence on this in detail, including how a managed taper differs from an abrupt stop.

For people who have paused treatment because of a supply issue, a missed delivery, or a gap between prescriptions, the same dynamic applies at a smaller scale. Even a few weeks without the medicine can be enough to notice appetite returning, and some people also find themselves wondering about how changes in body composition, including skin laxity, relate to the pattern of weight loss and regain. If you have had a gap in treatment, your prescriber should know, titration decisions may need revisiting. If you are thinking about cost and whether there is a more straightforward route to treatment, understanding how Wegovy is prescribed and supplied in the UK is a useful starting point.

When to speak to your prescriber, and what they can actually do

If you are gaining weight during active Wegovy treatment, the most useful thing you can do is document it: when the gain started, roughly how much, and whether anything else changed at the same time (dose, routine, other medicines, illness). A prescriber cannot adjust what they cannot see.

Options open to a clinician include reviewing whether you are at the right maintenance dose, whether the titration schedule needs adjustment, or whether any concurrent medicines or health changes might be interfering with response. Wegovy is also not the only licensed semaglutide option for weight management now; the recently approved oral semaglutide tablet may suit some patients differently. What is not on the table is guessing or waiting indefinitely, weight regain during treatment is a clinical signal worth acting on. If you would like a fresh set of clinical eyes on how treatment is going, speaking to our prescribers is a straightforward next step. Our clinical team, overseen by our lead prescriber, reviews every consultation personally. If you have broader questions first, the FAQs page covers many of the most common ones.